Takeda Pharmaceutical (NYSE:TAK) highlighted late-breaking Phase III data for investigational TYK2 inhibitor zasocitinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results